Tuberculosis

Tuberculosis Foundation Selects Core Research Scientists

Published in Vaccine Weekly, April 12th, 2000

In an initial step towards the development of a new vaccine to prevent tuberculosis (TB), the Sequella Global Tuberculosis Foundation has named 13 researchers to the Core Scientist Program of its Tuberculosis Vaccine Collaboration (TBVC) program.

Acting as a focused research team, these core scientists will help to guide the Foundation as it supports new and innovative tuberculosis vaccine development.

"What we are trying to do in the Core Scientist Program is to accelerate the transition of experimental vaccines from the research bench to the clinic. The three major areas addressed by this program are clinical trial site development, new tools for...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2000-04-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry